PHARMACOKINETIC (PK), PHARMACODYNAMIC (PD), AND TOLERABILITY OF OSILODROSTAT IN PEDIATRIC PATIENTS WITH CUSHING'S syndrome

Is your child suffering from Cushing’s syndrome? You may consider their participation in LINC-5 study which evaluates the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.

• Sponsor: Recordati Rare Diseases
• Contact:
  • Dr. Maya Lodish [email protected] University of California San Francisco, CA
  • Dr. Cristina Tatsi [email protected] National Institute of Child Health & Human Development, MD
• Who should consider participating: Children and adolescents 2 to <18 years of age with Cushing’s syndrome may qualify to participate in the LINC-5 study
• To learn more, please visit: https://clinicaltrials.gov/study/NCT03708900